Enterome secures $19m for EO2463 immunotherapy development

Enterome has successfully acquired $19 million in private financing to advance its EO2463 OncoMimics immunotherapy. This groundbreaking treatment is focused on combatting indolent non-Hodgkin’s lymphoma (iNHL). The funding will facilitate the expansion and conclusion of the ongoing Phase I/II SIDNEY trial and set the stage for a forthcoming registrational trial.

The financing round saw significant contributions from the Institute for Follicular Lymphoma Innovation (IFLI), a new investor from the US, which provided $9 million. Of this, $5 million is immediately accessible to Enterome, with an additional $4 million pending under conditional agreements. Existing investors, including Seventure Partners, SymBiosis, Lundbeckfonden BioCapital, the US Leukemia & Lymphoma Society Therapy Acceleration Program, and Primo Capital, collectively contributed an additional $10 million.

EO2463 is a promising immunotherapy candidate comprised of four synthetic OncoMimics peptides. This treatment is specifically designed to target B-cell markers and aims to eliminate malignant B lymphocytes. By addressing a broad spectrum of targets on malignant B cells, EO2463 seeks to enhance both safety and efficacy, while reducing the likelihood of tumor cells developing immune resistance mechanisms, such as antigen escape.

Enterome has recently revealed its intention to present new data at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21, 2025. This data will demonstrate the impact of EO2463 when combined with standard care for patients with relapsed and refractory iNHL. According to Enterome, the OncoMimics platform, which underpins EO2463, was inspired by the microbial origins of specific autoimmune conditions. The company effectively utilizes machine learning and AI technologies to identify microbial proteins that mimic certain cancer antigens.

Pierre Bélichard, CEO of Enterome, expressed enthusiasm about the current clinical proof of concept data being generated for EO2463 monotherapy across various iNHL patient populations included in the Phase I/II SIDNEY clinical trial. Bélichard highlighted EO2463’s notable clinical efficacy, as well as its exceptional safety and tolerability — a remarkable achievement for such a potent immunotherapy. He emphasized that the new financing would empower Enterome to continue the SIDNEY trial of EO2463 and prepare to initiate a pivotal Phase III trial tailored to the 'watch-and-wait' population affected by iNHL.

The funds raised will play a crucial role in driving further research and development, aiming to solidify EO2463's position as a transformative treatment option for patients battling indolent non-Hodgkin’s lymphoma. By doing so, Enterome is poised to make significant strides within the oncology field, providing new hope for individuals with challenging and resistant forms of lymphoma.

Overall, Enterome’s dedication to advancing cancer therapy through innovative immunotherapy solutions marks a significant milestone in the ongoing fight against lymphoma. With the backing of strong investors and continued research efforts, EO2463 has the potential to redefine treatment paradigms and offer improved outcomes for patients enduring this formidable disease.